A Prokinetic Approach to Treatment of Gastroesophageal Reflux Disease

Digestive Diseases

Volumn 16, Issue 1, 1998, Pages 38-46

  Achem, Samir ^a   Robinson, Malcolm ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Acid suppressive therapy; Antireflux therapy; Esophageal motility; Esophageal reflux; Prokinetic agents

Indexed keywords

ANTIULCER AGENT; ENZYME INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST;

DRUG COMBINATION; GASTROESOPHAGEAL REFLUX; HUMAN; REVIEW;

ANTI-ULCER AGENTS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS;

EID: 0031601647     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000016847     Document Type: Review

References (56)

1. Graham DY, Smith JL, Patterson DJ: Why do apparently healthy people use antacid tablets? Am J Gastroenterol 1983;78:257-260.
2. Robinson M, Earnest DL, Maton PN, et al: Frequent heartburn symptoms should not he ignored in subjects who self treat with antacids. Gastroenterology 1996;110:A214.
3. Decktor D, Robinson M, Gottlieb S: Comparative effects of liquid antacids on esophageal and gastric pH in patients with heartburn. Am J Ther 1995;2:481-486.
4. Chelikani S, Robinson M, Maton PN, Rodriguez S: Comparison of tablet and liquid antacids on acidity in the esophagus and stomach. Am J Gastroenterol 1995;90:1570.
5. Janes DB, Howden CW, Burget DW, et al: Acid suppression in duodenal ulcer. A metaanalysis to define optimal dosing with antisccretory drugs. Gut 1987;28:1120-1127.
6. Sontag SJ: The medical management of reflux esophagitis: Role of antacids and acid inhibition. Gastroenterol Clin North Am 1990;19: 683-712.
7. Bell NJ, Hunt RH: Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992;33:118-124.
8. Chiba N, de Gara CJ, Burget DW, et al: Rapidity of healing in GERD: A comparison of different drug classes by meta-analysis. Gastroenterology 1993;104:A53.
9. Palmer RH, Frank WO, Rockhold FW, et al: Cimetidine 800 mg twice daily for healing erosions and ulcers in gastroesophageal reflux disease. J Clin Gastroenterol 1990;12:S29-S34.
10. Roufail W, Belsito A, Robinson M, et al: Ranitidine for erosive esophagitis: A double-blind, placebo-controlled study. Aliment Pharmacol Ther 1992;6:597-607.
11. Sharma BK, Walt RP, Pounder RE, et al: Optimal dose of oral omeprazole for maximal 24-hour decrease of intragastric acidity. Gut 1984; 25:957-964.
12. Barradell LB, Faulds D, McTavish D: Lansoprazole: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44:225-250.
13. Fitton A, Wiseman L: Pantoprazole: A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996;51:460-482.
14. Dammann HG, Burkhardt F, Bell NE, Bjaaiand T: Rabeprazolc effectively inhibits 24 hr H+ activity and nocturnal acid secretion in healthy subjects. Gut 1996;39(suppl 3):A47.
15. Chiba N, de Gara CJ, Burget DW, et al: Rapidity of healing in GERD: A comparison of different drug classes by meta-analysis. Gastroenterology 1993,104(4 pt 2):A53.
16. Castell DO, Richter JE, Robinson M, Sontag S: Large trial compares lansoprazole to omeprazole. Gastroenterology 1995;108(4 suppl):A67.
17. 2-receptor antagonists. Am J Med 1987; 83(suppt 6A):58-67.
18. 2-receptor antagonists: Standard therapy for acid-peptic diseases. N Engl J Med 1990; 323:1672-1680, 1749-1755.
19. Ramirez B, Richter JE: Promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993;7:5-20.
20. Saco LS, Orlando RC, Levinson SL, et al: Double-blind controlled trial of bethanechol and antacid versus placebo and antacid in the treatment of erosive esophagitis. Gastroenterology 1982;82:1369-1373.
21. Bright-Asare P, El-Bassoussi M: Cimetidine, metoclopramide, or placebo in the treatment of symptomatic gastroesophageal reflux. J Clin Gastroenterol 1980;2:149-156.
22. McCallum RW, Ippoliti AF, Cooner C, et al: A controlled trial of metoclopramide in symptomatic gastroesophageal reflux. N Engl J Med 1977;296:354-357.
23. Thanik KD, Chcy WY, Shak AN, et al: Reflux esophagitis: Effect of oral bethanechol on symptoms and endoscopic findings. Ann Intern Med 1980;93:805-808.
24. Masci E, Testoni PA, Passaretti S, et al: Comparison of ranitidine, domperidone maleate. and ranitidine + domperidone maleate in the short-term treatment of reflux esophagitis. Drugs Exp Clin Res 1985;11:687-692.
25. Richter JE, Long JF: Cisapride for gastroesophageal reflux disease: A placebo-controlled, double-blind study Am J Gastroenterol 1995; 90:423-430.
26. DeMicco M, Berenson M, Wu W, et al: Cisapride in the treatment of GERD: A double-blind, placebo-controlled multicenter dose-response trial. Gastroenterology 1992;102:A59.
27. Dodds W, Champion M, Orr W, et al: Oral cisapride in GERD: A double-blind placebo-controlled multicenter trial. Gastroenterology 1989;96:A126.
28. Robertson CS, Evans DF, Ledingham SJ, Atkinson M: Cisapride in the treatment of gastrooesophageal reflux disease. Aliment Pharmacol Ther 1993;7:181-190.
29. Janiseh HD, Huttemann W, Bouzo MH: Cisapride versus ranitidine in the treatment of reflux esophagitis. Hepato-gastroenterol 1988; 35:125-127.
30. Galmiche JP, Fraitag B, Filoche B, et al; Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Dig Dis Sci 1990;35:649-655.
31. Geldof H, Hazelhoff B, Otten MH: Two different dose regimens of cisapride in the treatment of reflux oesophagitis: A double-blind comparison with ranitidine. Aliment Pharmacol Ther 1993;7:409-415.
32. Wiseman LR, Faulds D: Cisapride: An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994;47: 116-152.
33. Sandmark S, Carlsson R, Faussa O, et al: Omeprazole or ranitidine in the treatment of reflux esophagitis: Results of a double-blind, randomized. Scandinavian multicenter study. Scand J Gastroemerol 1988;23:625-632.
34. Sontag S, Robinson M, Roufail W, et al: Daily omcprazole is needed to maintain healing in erosive esophagitis: A US, multicenter, double-blind study. Am J Gastroenterol 1992; 87:A1258.
35. Hetzel DJ, Dent J, Reed WU, et al: Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-912.
36. Lieberman DA: Medical therapy for chronic reflux esophagitis: Long-term follow-up. Ann intern Med 1987;147:1717-1720.
37. Toussaint J, Gossuin A, Deruyttere M, et al: Healing and prevention of relapse of reflux oesophagitis by cisapride. Gut 1991;32:1280-1285.
38. Tytgat GNJ, Hansen OJA, Carling L, et al: Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug. Scand J Gastroenterol 1992;27:175-183.
39. Blum AL, Adami B, Bouzo MH, et al: Effect of cisapride on relapse of esophagitis: A multinational, placebo-controlled trial in patients healed with an antisecretory drug. Dig Dis Sci 1993;38:551-560
40. Simon TJ, Roberts WG, Berlin RG, Hayden LJ, Berman RS, Reagan JE: Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopie recurrence of erosive esophagitis. Clin Ther 1995; 17:1147-1156.
41. Sontag S, Vlahcevic ZR, Orr WC, et al: Ranitidine versus placebo in long-term treatment of gastroesophageal reflux. Gastroenterology 1985;88:1595A.
42. Antonson C, Robinson M, Hawkins T, McIntosh D, Campbell D: High doses of histamine antagonists do not prevent relapses of peptic esophagitis following therapy with a proton pump inhibitor. Gastroenterology 1990;98: A16.
43. Laursen LS, Havelund T, Bondesen S, et al: Omeprazole in the long-term treatment of gastro-oesophageal reflux disease; A double-blind randomized dose-finding study. Scand J Gastroenterol 1995;30:839-846.
44. Robinson M, Lanza F, Avner D, Haber M: Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:859-867.
45. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al: Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole of fundoplication. N Engl J Med 1996;334:1018-1022.
46. Weinstein WM, Ippoliti AF, Lee SW, Weber LJ, Lieberman DA: Acid hypersecretion, parietal cell hyperplasia, and endoscopic changes after withdrawal of long term high dose omeprazole therapy: A prospective study. Gastroenterology 1996;110:A294.
47. Dent J, Yeomans ND, Mackinnon M, et al: Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis: A controlled double blind trial of their efficacy and safety. Gut 1994;35:590-598.
48. Hallerback B, Unge P, Carling L, et al: Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 1994;107: 1305-1311.
49. Lundell L: Prevention of relapse of reflux oesophagitis after endoscopic healing: The efficacy and safety of omeprazole compared with ranitidine. Digestion 1990;47(suppl 1):72-75.
50. Vigneri S, Termini R, Leandro G, et al: A comparison of five maintenance therapies for reflux esophagitis N Engl J Med 1995;333:1106-1110.
51. Kitchin LI, Castell DO: Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med 1991;151:448-454.
52. Reynolds JC: Individualized acute treatment strategies for gastroesophageal reflux disease. Scand J Gastroenterol 1995;30(suppl 213):17-24.
53. Sontag SJ: Rolling review: Gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7:293-312.
54. Kuster E, Ros E, Toledo-Pimentel V, et al: Predictive factors of the long term outcome in gastro-oesophageal reflux disease: Six year follow upof 107 patients. Gut 1994;35:8-14.
55. Tytgat GNJ, Janssens J, Reynolds JC, Wienbeck M: Update on the pathophysiology and management of gastro-oesophageal reflux disease: The role of prokinetic therapy. Eur J Gastroenterol Hepatol 1996;8:603-611.
56. Kimmig JM: Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: Comparison of two strategies. Aliment Pharmacol Ther 1995;9.281-286.